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1 2 1 2 VOLUME 49 | NUMBER 8 | AUGUST 2017 Nature GeNetics A r t i c l e s encode epigenetic regulators and chromatin modifiers are also mutated in T-ALL, including EED, EZH2 and SUZ12, which encode core components of polycomb repressor complex 2 (PRC2). PRC2 mediates the repressive histone H3 lysine 27 trimethylation mark; KDM6A, which encodes a histone demethylase 29, 30 ; and USP7, which encodes a deubiquitinating enzyme 31 . Several intracellular signaling pathways are activated by mutation, including the PI3K-AKT-mTOR pathway, most commonly affected by PTEN deletion 18, 32 , PTPN2 deletion 33 or AKT1 mutation 34 ; the JAK-STAT pathway via activating mutations in the interleukin 7 receptor α-chain gene (IL7R) 35, 36 , JAK1 (ref. 37) , JAK3 (refs. 38, 39) or STAT5B 40 ; Ras-MAPK signaling through KRAS and NF1 mutation 24, 41 ; and chimeric ABL1 fusion genes such as NUP214-ABL1 and ETV6-ABL1 (refs. 20,21) . Mutations in ribosomal biogenesis processing have recently been identified, including in RPL5, RPL10 and RPL11 (ref. 42 ) and in the plant homeodomain factor gene PHF6, which has a putative role in chromatin modification 43 .
Although these data have provided important insights into the oncogenic pathways that drive leukemogenesis in T-ALL, there are relatively few data from unbiased, genome-wide sequencing approaches, and those available have usually encompassed relatively small cohorts 24, 44 , gene panels 31, 45 or a single modality of sequencing 42, 46 . Here we carried out an integrated, multimodality genomic analysis of a uniformly treated cohort of pediatric and young adult subjects with T-ALL to identify the spectrum and constellations of genetic alterations in this disease.
RESULTS

Molecular classification of T-ALL
In a collaborative study by the Children's Oncology Group, the National Cancer Institute Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative and the St. Jude-Washington University Pediatric Cancer Genomic Project, we studied 264 children and young adults with newly diagnosed T-ALL who had consecutively enrolled in Children's Oncology Group trial AALL0434 (ref. 47 ) between 2007 and 2011 and for whom tumor and remission material was available ( Supplementary Tables 1 and 2) . DNA extracted from tumor and remission samples was subjected to whole-exome sequencing and single-nucleotide polymorphism microarray genotyping, and tumor RNA was subjected to transcriptome sequencing (RNA-seq) ( Supplementary Tables 3-5 ). We verified a subset of previously unreported or complex sequence mutations and mutations of the TAL1 enhancer 48, 49 by amplicon-based nextgeneration sequencing ( Supplementary Table 6 ). Immunophenotypic data were available for all cases, and 189 (71.6%) cases included data that enabled us to carry out subclassification into ETP ALL (19 cases), near-ETP (24 cases fulfilling criteria for ETP ALL, but with normal CD5 expression) 4 and non-ETP ALL (146 cases) groups.
On the basis of genetic alterations and dysregulated expression of transcription factor genes, as well as hierarchical clustering of RNA-seq gene expression data, we classified 242 (91.7%) subjects into eight subgroups with deregulation of one of the following genes: TAL1 (n = 87), TAL2 (n = 8), TLX1 (n = 26), TLX3 (n = 46), HOXA (n = 33), LMO1/LMO2 (n = 10), LMO2/LYL1 (n = 18) and NKX2-1 (n = 14) ( Supplementary Table 1 and Supplementary Fig. 1 ). ETP ALL cases commonly showed LMO2/LYL1 deregulation (7 of 19 cases; 36.8%), near-and non-ETP ALL cases were enriched for TAL1 deregulation (41.7% and 27.4%, respectively), TLX3 deregulation was most commonly observed in near-ETP cases, and TLX1 deregulation was most common in the non-ETP ALL group (χ 2 P = 0.0004; Supplementary Table 7) .
Sequence mutations in pediatric T-ALL
We identified 4,165 nonsynonymous single-nucleotide variant (SNV), insertion/deletion (indel) or internal tandem duplication sequence mutations in 2,694 genes by exome sequencing or RNA-seq in the cohort of 264 samples, with a mean of 15.8 mutations (range: 2-50) per case ( Supplementary Table 8 ). We used the mutation-significance detection tools MutSigCV 50 , MuSiC 51 and Medal Ceremony and mutant-allele expression data to identify potential driver mutations. Figure 1 The 55 most common targets of sequence mutation in T-ALL. Left, genes with mutations listed in order of recurrence and stratified by mutation type. Gene symbols in blue are those previously found to be mutated in adult T-ALL cases but not in children. Those in red have not previously been reported in T-ALL. Asterisks indicate genes on chromosome X. The column labeled "%Sample" represents the number of mutations for each gene per case. The far-right column shows the MAF of sequence mutation across the cohort.
Importantly, 24 genes harboring somatic mutations of known functional significance were mutated in only a single case, including EP300 (p300), KIT and TP53. Overall, we identified 106 driver genes ( Supplementary Table 9 ), including known targets of mutation in T-ALL: NOTCH1 (n = 197 cases (74.6%), including 5 cases with intragenic NOTCH1 deletions), FBXW7 (63; 23.9%), PHF6 (50; 18.9%), PTEN (37; 14.0%), USP7 (31; 11.7%), DNM2 (29; 11.0%), BCL11B (26; 9.8%), WT1 (24; 9.1%), JAK3 (20; 7.6%), NRAS (20; 7.6%), IL7R (18; 6.8%), PIK3R1 (17; 6.4%) and RPL10 (16; 6.1%) ( Fig. 1 and Supplementary Fig. 2 ). Fifty-three (51%) of these 106 genes, and 39 (48%) of 82 recurrently mutated genes, had not previously been observed as mutated in pediatric T-ALL 24, 31, 34, 42, 44 . These included the transcriptional regulatory genes MYB (n = 13), CNOT3 (n = 9), MED12 (n = 7), MYCN (n = 6) and TSPYL2 (n = 4); epigenetic regulators including CTCF (n = 13), SMARCA4 (n = 7) and CREBBP (n = 5); cell cycle genes including CCND3 (n = 15) and CDKN1B (n = 4); the deubiquitination gene USP9X (n = 7); RNA-processing genes including DDX3X (n = 4) and U2AF1 (n = 4); genes in which mutations are predicted to activate PI3K-AKT signaling, such as PIK3CD (n = 5); and ZFP36L2, which encodes an RNA-binding protein and suppressor of NOTCH1 expression (n = 5; three mutations and three fusions) 52, 53 . Four genes (CNOT3, KMT2D, RPL5 and FAT1) were previously identified as mutated in adult, but not pediatric, T-ALL. We observed subclonal mutations (defined as those with a mutant allele fraction (MAF) of <0.3) frequently in many driver genes ( Fig. 1) , which indicated that subclonal evolution is a hallmark of T-ALL. Moreover, many cases harbored multiple subclonal mutations in the same gene, indicating that these mutations are secondary events in leukemogenesis but exert driver functions in individual subclones. For example, NOTCH1 was the most frequently mutated gene, with 264 sequence mutations identified in 196 cases, and most mutations in the heterodimerization domain (62.9%; 166/264) or PEST domain (31.4%; 83/264). Although subclonal NOTCH1 mutations have been reported previously, the extent of multi-and subclonality identified in this study is substantially greater that previously described 54 . Of the 264 mutations, 116 (43.9%) were subclonal. Fifty-eight (29.6%) samples harbored multiple NOTCH1 mutations (49 samples with two mutations, and 9 samples with three mutations).
To determine whether germline sequence mutations may influence a person's risk of developing T-ALL, we analyzed 89 genes ( Supplementary Table 10 ), including 60 associated with autosomal dominant cancer predisposition syndromes 55 and the 35 most frequent targets of somatic mutation in this study. We identified only four potentially deleterious germline mutations, in BRAF, BRCA1, BRCA2 and RUNX1 (Supplementary Note 1).
Gene rearrangements in pediatric T-ALL
Analysis of transcriptome sequencing data identified transcripts derived from 255 gene rearrangements in 191 (72.3%) samples ( Supplementary Table 11 ). We identified 83 chimeric in-frame fusions, 54 of which arose from interchromosomal rearrangements, and 29 from intrachromosomal events. The most frequent were fusions of MLLT10 (six unique rearrangements in 13 cases), KMT2A (six fusions in 12 cases), ABL1 (four fusions in 5 cases) and NUP98 (four fusions in 5 cases) ( Table 1) . We also identified several novel fusions involving signaling pathways, transcriptional regulation or RNA processing, including ETV6-CTNNB1, IL9R-VAMP7, PCM1-JAK2, CD99-JAK2, CSTF3-LMO2, STMN1-SPI1 and NCOR1-NFIA (one case each). The second class of rearrangements identified by RNA-seq was those that deregulate oncogenes, including TAL1 (n = 58), TLX1 (n = 17), TLX3 (n = 13) and TAL2 (n = 6). Importantly, this analysis not only identified previously unreported rearrangement partners and/or mechanisms of deregulation for known targets of rearrangement, but also showed that transcriptome sequencing does not identify all rearrangements, notably cases with TLX3 deregulation (Supplementary Note 1, Supplementary Table 12 and Supplementary Fig. 3 ). Whole-genome sequencing (WGS) of 25 cases that lacked a rearrangement identified 5 additional cases with rearrangements of core T-ALL transcription factor genes that were not identified by analysis of transcriptome sequencing data, as the breakpoints were located in intergenic regions and the rearrangements did not result in the expression of a chimeric fusion product: TRA-LMO2, TRB-TAL2, BCL11B-TLX3 and NKX2-1 (Supplementary Table 1 ).
The transcription factor gene MYB was altered by amplification (n = 33), rearrangement (n = 11) or mutation (n = 13) in 49 (18.6%) cases ( Supplementary Fig. 4 ). We identified multiple mechanisms of rearrangement, including juxtaposition of the 5′ region of MYB to promoter/enhancer regions of partner genes (TRB; n = 2) and SLC12A9 (n = 1). We identified rearrangements of the 3′ region of MYB that resulted in the loss of a negative regulatory region in three cases (involving PLAGL1, BDP1 and CHMP1A; n = 1 each). We identified 14 MYB mutations in 13 samples, including a novel hot spot of missense and in-frame insertion mutations at codon 14 in seven cases (Supplementary Fig. 2 ). This residue lies in an unstructured region of MYB adjacent to a nuclear localization sequence that may perturb the intracellular localization, and thus activity, of MYB.
Recurrently targeted pathways in pediatric T-ALL
We integrated sequence mutation, structural variant/rearrangement and DNA copy-number alteration data ( Supplementary Tables 13 and 14) (7), TRA (5), TLX1-upstream (4), LINC00502-TLX1 (1)
AHI1-MYB (5) rearrangements resulting in chimeric fusions
Gene n Partner gene
and identified ten functional pathways that were recurrently mutated in T-ALL: transcriptional regulation (91% of cases), cell cycle regulation and tumor suppression (84%), NOTCH1 signaling (79%), epigenetic regulation (68%), PI3K-AKT-mTOR signaling (29%), JAK-STAT signaling (25%), Ras signaling (14%), ribosomal function (13%), ubiquitination (9%) and RNA processing (9%) ( Fig. 2 and Supplementary Tables 15 and 16 ). Most commonly mutated were transcriptional regulators, including those oncogenes that define T-ALL subgroups (for example, TAL1, TLX1, TLX3, LMO2 and NKX2-1), known recurrently mutated genes (MYB, LEF1 and BCL11B) and 16 genes that were mutated in fewer than ten cases ( Supplementary Fig. 5 ).
Genes encoding regulators of cell cycle progression and/or tumor suppressors were mutated in 83.7% of cases, with the recurrent targets of alteration being CDKN2A/CDKN2B (78.4%), CDKN1B (12.9%), RB1 (9.5%) and CCND3 (6.1%), and single mutations observed in CASP8, CDKN2C and TP53. In addition, broad deletions of chromosome 6q14-q23 were present in 19.3% of cases, and were enriched in TAL1 cases (Supplementary Note 1, Supplementary Table 17 and Supplementary Figs. 6-8) .
We observed mutations that activate NOTCH1 signaling in 79% of cases, including mutations in NOTCH1 (74.6%; 149 heterodimerization, 78 PEST), FBXW7 (25.4%) or both (20.8% cases) (n = 55) ( Supplementary Fig. 9 ).
We observed significant association between mutations and T-ALL subtypes, and variation in the frequency of genes and pathways mutated across T-ALL subtypes, consistent with the notion that such subtype-enriched genomic alterations reflect genes critical to specific stages of T cell development ( Fig. 3, Supplementary Tables 18 and 19 , and Supplementary Fig. 10) . Notably, we observed mutations in the NOTCH1 signaling pathway in nearly all LMO1/LMO2, NKX2-1 and TLX1 cases, but less frequently in TAL1/TAL2 and LMO2/LYL1 cases. Epigenetic mutations were particularly common in TLX3 cases (93.5%), and ribosomal processing mutations were highly enriched in NKX2-1 cases (50.0%).
Excluding CDKN2A, NOTCH1 and FBXW7, which are mutated in multiple T-ALL subtypes, we identified the 37 most recurrently mutated genes that were significantly enriched in at least one T-ALL subtype. We constructed a network to link mutations to T cell developmental stages, considering both gene-subgroup and genegene correlation (Fig. 3) . Mutations of genes in the JAK-STAT or Ras signaling pathway (for example, FLT3, NRAS and JAK3) were enriched in the LMO2/LYL1 and HOXA subgroups, whereas those of the PI3K signaling pathway (commonly PTEN and PIK3R1) were enriched in the TAL1 subgroup, suggesting a transition of the predominant signaling pathway from early T cell development to later stages. We noted significant enrichment of USP7 alterations in the TAL1 subgroup, CTCF alterations in TLX3 cases, and DNM2 and PHF6 alterations in TLX1/TLX3 cases, suggesting that different epigenetic regulators are involved in the early versus late cortical stages of T cell development. Alteration of the transcription factor gene LEF1 was most common in NKX2-1 cases, and changes in BCL11B or MYC were most common in TLX1 cases. Mutations in RPL5 and RPL10 were enriched in the TLX3 and NKX2-1 subgroups, respectively, suggesting that these two ribosome biogenesis genes may have distinct roles in early and late cortical development. MYB (n = 49), IL7R (n = 18) and ABL1 (n = 18, including three cases with NUP214-ABL1, one with NUP214-ABL1 and ETV6-ABL1, one with MBNL1-ABL1, one with an in-frame ABL1 deletion, and the remainder with broad amplification of 9q; Supplementary Note 1 and Supplementary Fig. 11 ) were the most frequently mutated genes that were not associated with a subtype, which suggests that they may drive signaling pathways in multiple stages of T cell maturation.
Somatic alterations targeting transcriptional regulators
In addition to alterations of transcription factor genes that define T-ALL subgroups, we observed mutation of 26 transcription factor genes, with 24 mutated in more than one case 56 (Supplementary  Fig. 5) . A previously unreported mutation in T-ALL was the MYCN Figure 2 Recurrently mutated pathways in T-ALL. The diagram shows ten recurrently mutated pathways and the proportion of cases in each T-ALL subgroup. The majority of pathways showed significant associations between prevalence of alteration and T-ALL subgroup (**P < 0.01, X 2 ). Figure 3 A network depicting associations between genetic alterations and T-ALL subgroups and stages of T cell development. Nodes represent genetic alterations and are color-coded according to the T-ALL subtype in which they are most enriched. The size of each node represents the frequency of the genetic alteration across the entire cohort (see the key in the lower left corner). The thickness of lines connecting the nodes indicates the statistical significance of co-occurrence of a gene-gene or gene-subtype pair. Intra-and intersubtype co-occurrence are indicated by red and blue lines, respectively. Nodes in gray represent genetic alterations that were not specifically enriched in a T-ALL subtype. mutation encoding p.Pro44Leu (P44L), which we identified in six cases (Fig. 4a) . This mutation has previously been identified in neuroblastoma and is associated with elevated levels of MYCN expression, suggesting a role in oncogenesis 57 . The altered residue lies adjacent to the conserved phospho-degron recognized by E3 ubiquitin ligases FBXW7, SKP2 and HUWE1, consistent with the possibility that this mutation may perturb MYCN protein levels or protein-protein interactions [58] [59] [60] . To examine the functional consequences of this mutation, we transduced Cdkn2a −/− mouse thymocytes with lentiviral vectors expressing either wild-type or P44L MYCN. We cultured transduced cells on OP9-DL1 cells and transplanted them after 10 d into irradiated Rag2 −/− recipient mice 61 . Both wild-type and mutant MYCN vectors induced a highly penetrant T-lineage leukemia, but we observed a modest but significantly shorter latency in cells that expressed the mutant P44L MYCN vector ( Fig. 4b-d) . To explore the hypothesis that this mutation may perturb ubiquitin-mediated degradation, we transfected NIH3T3 cells with wild-type or mutant hemagglutinin (HA)-tagged MYCN lentiviral vectors, treated the cells with cycloheximide to block protein translation, and quantified MYCN protein levels over time by immunoblotting. We observed significantly slower decay of P44L MYCN compared with that of the wildtype protein (Fig. 4e,f) , consistent with the notion that this mutation impairs protein degradation and thereby enhances oncogenicity.
TAL1-deregulated ALL was the most common subtype of T-ALL in this study (87 cases (33.0%)). Fifty-nine cases had structural alterations identified by RNA-seq or single-nucleotide polymorphism array analysis (51 with deletions that resulted in STIL-TAL1 fusion, and 8 with other TAL1 rearrangements), but a substantial minority lacked such an alteration. Recently, a noncoding insertion mutation upstream of the TAL1 locus was reported that creates a MYB-binding site, resulting in recruitment of CREBBP (CBP), acetylation of histone 3 on lysine 27, and recruitment of RUNX1, GATA3 and TAL1 (ref. 48) . We identified 15 cases (5.7%) with identical or similar TAL1 mutations that resulted in acquisition of the MYB-binding motif. Notably, we identified a distinct indel mutation in four additional cases that resulted in the acquisition of TCF1/TCF2 motifs and loss of a GMEB1 binding motif, suggesting a distinct mechanism for TAL1 deregulation in these cases (Supplementary Fig. 12 ). The remaining 11 TAL1 cases lacked a known genomic mechanism for gene deregulation.
Additional mutated transcription factor genes included MED12 (n = 7) and TSPYL2 (n = 4) ( Supplementary Fig. 2) . MED12 encodes part of the kinase module of the large MEDIATOR complex that bridges a range of transcriptional pathways to RNA polymerase 2 and transcription, and is mutated in several different types of tumors 62 . The majority of mutations that we observed were frame-shift or nonsense mutations, which suggests that these are tumor suppressor genes in T-ALL. Thirty-two cases had focal deletions or gains of chromosome 8q distal to MYC at or adjacent to the NOTCH1 MYC enhancer region that interacts with the MYC locus and facilitates MYC expression 63, 64 (Supplementary Fig. 13) . These alterations were most common in the HOXA and TLX1/TLX3 subgroups, and included deletions in addition to the previously reported amplifications, both of which were associated with elevated MYC expression (data not shown).
Signaling pathway mutations in T-ALL
We observed mutations that activated signaling pathways in 65% of cases. These included the PI3K-AKT (28.8% of cases), JAK-STAT (24.6%) and Ras signaling (13.6%) pathways, and rearrangements involving ABL1, ADGRG7 (GPR128), IL2RB and IL9R (Fig. 5) . We observed exclusivity between PI3K-AKT pathway and JAK-STAT or Ras pathway alterations (P < 0.0001, Fisher's exact test), with PI3K-AKT mutations prevalent in TAL1 cases, and JAK-STAT or Ras mutations in TLX1/TLX3 and HOXA cases. Although PTEN, PIK3R1 and AKT1 were the most commonly mutated genes in the PI3K-AKT pathway, we also identified several mutations previously unreported in T-ALL. These included a recurrent somatic PIK3CD mutation encoding p.Glu1021Lys, which we observed in five cases (four TAL1 and one LMO2/LYL1). This has been reported to be a dominant AKT-activating germline mutation 65 . Other recurring alterations resulting in the activation of signaling pathways included rearrangement of ABL1 and TFG-ADGRG7 (TFG-GPR128), a rearrangement also observed in high-risk B-lineage ALL and lymphoma (n = 3) 66 .
Fifty-five cases (20.8%) had multiple signaling mutations, with 13 cases carrying at least three mutations. The most common patterns were a JAK-STAT activating mutation and concomitant mutations involving additional JAK-STAT (n = 19), Ras (n = 11), PI3K-AKT (n = 6) or other mutations (n = 6), or PI3K-AKT mutations with A r t i c l e s secondary PI3K-AKT (n = 13), Ras (n = 4) or other mutations (n = 3). This raised the question of whether these concomitant mutations reside in the same or distinct clones. This is of importance for the selection of targeted therapeutic approaches and for the potential for the emergence of subclones resistant to agents that target a single pathway. To address this, we examined the MAF of signaling pathway mutations in 14 cases with JAK3 sequence mutations. Thirteen of the cases carried a JAK3 variant with MAF > 0.3 (30%), indicating that the mutations were present in a predominant/major clone (Supplementary Fig. 14) . In ten of these cases, the signaling mutation with the next highest MAF (including the JAK-STAT and Ras pathways) was also clonal. In three cases, the JAK3 mutation was clonal, but the second signaling mutation was subclonal, indicating that both mutations coexisted in a subclone. In one case, both mutations were subclonal, and may have existed in the same or different clones. Thus, in the majority of cases, the most common JAK-STAT and second most common signaling mutations coexisted in the same clone.
Patterns of epigenetic mutation in T-ALL
Epigenomic regulators were recurrently mutated in all T-ALL subgroups, with the exception of TAL2-rearranged ALL (0 of 8 cases), with a prevalence ranging from 10 of 18 (55.6%) LMO2/LYL1 cases to 43 of 46 (93.5%) TLX3 cases ( Supplementary Table 19 and Supplementary  Fig. 15 ). In addition to the known association between PHF6 mutations and TLX3 rearrangement 43 , we observed several additional associations between mutation and subtype. We observed alterations of USP7 almost exclusively in TAL1 cases (29 of 33 USP7 mutations). USP7 encodes a ubiquitin-specific protease that stabilizes MDM2 and TP53 (ref. 67 ). The majority of mutations (76.5%) were heterozygous out-offrame indel (n = 25) or nonsense (n = 1) mutations in or proximal to the catalytic domain, indicating that these mutations result in loss of function ( Supplementary Fig. 2) . Additional gene mutations associated with T-ALL subtypes included CTCF (56.0% of 25 mutations) and
KDM6A (42.9% of 21 mutations) in TLX3 cases, and KMT2A (77.8% of 18 mutations) in HOXA cases ( Supplementary Table 19 ).
Mutational spectra of ETP and non-ETP T-ALL
ETP ALL has been described as a distinct form of leukemia with characteristic immunophenotypic, transcriptomic, genetic and clinical features compared with other T-ALL types 3 . Prior studies have reported a mutational spectrum enriched for mutations in transcriptional, epigenetic and signaling genes more characteristic of myeloid malignancies 3, 68 . As expected, many (7 of 19) of our ETP ALL cases fell in the LMO2/LYL1-overexpressing group, but there were additional cases in the HOXA (n = 3), TAL1 (n = 2) and TLX3 (n = 4) subgroups ( Supplementary Table 6 ). Alterations in transcriptional regulators were nearly universal, occurring in 89.5% of ETP ALL, 87.5% of near-ETP and 89.0% of non-ETP cases. Alterations in JAK-STAT signaling (47.4% versus 25.0%/21.9%; P = 0.05), Ras signaling (36.8% versus 20.8%/10.3%; P = 0.005) and epigenetic regulation (84.2% versus 83.3%/65.8%; P = 0.08) were more common, and cell cycle alterations (31.6% versus 87.5%/87.0%; P < 0.001) were less common ( Supplementary Table 19 ). Genes more frequently altered in ETP ALL included FLT3 (5 of 9 ETP cases; P < 0.001), WT1 (8 of 21 ETP cases; P < 0.001), IKZF1 (3 of 8 ETP cases; P = 0.029) and MED12 (4 of 6 ETP cases; P < 0.001); we also noted frequent rearrangement of NUP98 (3 of 4 ETP ALL cases; P < 0.001). FLT3 was overexpressed in ETP compared with near-/non-ETP cases, with five of the eight cases with the highest FLT3 expression having concomitant mutations (data not shown). In contrast, genes less commonly mutated in ETP ALL were CDKN2A/ CDKN2B, CNOT3, DDX3X, FBXW7, LEF1, MYCN and RPL10, alterations of which were observed exclusively in non-ETP cases. A r t i c l e s AKT1, MLLT10, CNOT3 and PTEN alterations ( Supplementary Note 1 and Supplementary Tables 20-23) .
Genomic determinants of outcome
TRG 6q del PTEN (53) PIK3R1 (17) AKT1 (6) PIK3CA (5) PIK3CD (5) AKT2 (2) PIK3C2B (1) JAK3 (20) IL7R (18) PTPN2 (13) FLT3 (12) STAT5B (11) JAK1 (7) SH2B3 (3) JAK2 (3) IL2RB (1) NRAS (20) NF1 (8) KRAS (7) BRAF (3) PTPN11 (2) ABL1 (18) TFG (3) ABL2 (1) IL9R (1) KIT(1)
DISCUSSION
Although many of the most frequent mutations in T-ALL have been described previously, our integrated genomic analysis of a large cohort of T-ALL cases identified a large number of unrecognized targets of mutation and demonstrated stage-and subtype-specific associations among genes, cellular pathways and outcomes. Although many mutated genes reside in a 'long tail' of mutations, in silico functional analysis shows that many of these mutations are probably deleterious and contribute to the pathogenesis of ALL. Moreover, many such genes fall in pathways known to be affected in T-ALL (including the JAK-STAT, Ras and PTEN-PI3K signaling pathways), which increases the proportion of T-ALL cases with mutations in these pathways that are potentially amenable to therapeutic approaches with signal transduction inhibitors. We also show that many of the known targets of mutation are altered at greater frequencies than previously recognized (for example, NOTCH1), and that subclonal and multiclonal mutations are more prevalent than previously recognized. This is consistent with the notion that many of these mutations are acquired as secondary events subsequent to founding alterations that deregulate hematopoietic transcription factors. This is also a finding of potential therapeutic relevance, as we observed that multiple signaling mutations commonly co-occurred in the same clone. This provides a rationale for targeting these pathways in such cases. In addition to identifying previously unrecognized targets of mutation, the integrated analysis identified multiple new modalities of mutation in known T-ALL driver genes, including sequence mutations and enhancer alterations that deregulate MYCN, novel rearrangements and mutations of MYB, rearrangements and complex mutations of ZFP36L2, and novel TAL1 enhancer mutations. As proof of principle, we demonstrated that the MYCN mutations accelerated leukemogenesis, in part by stabilizing protein expression. This integrated analysis also suggests that genetic alterations, such as the common broad deletion of 6q, are likely to promote tumorigenesis by disrupting multiple genes, although this will require formal testing in models that engineer the deletion or disrupt the activity of multiple genes in the region simultaneously.
A limitation of this study is that we did not carry out WGS for all cases. Analysis of RNA-seq, exome and DNA copy-number data did not identify lesions that activated key transcription factors in a proportion of cases. Using WGS, we identified additional rearrangements in a subset of cases. Thus, comprehensive definition of the genomic landscape of T-ALL will require this approach.
The multi-modality genomic analysis conducted for all cases enabled a detailed analysis of associations between mutated genes and subtypes of ALL that are considered to arise at defined stages of thymic development. We show that although several pathways contained mutations in the majority of cases, mutations in certain individual genes (for example, JAK-STAT, Ras or PTEN gene mutations; ETV6 or RUNX1 transcription factor gene mutations; and PHF6 and USP7 epigenetic mutations) were significantly enriched in different ALL subtypes. This suggests not only that these alterations are leukemogenic cooperative driver events in which the founding alterations deregulate transcription factors, but also that these genes may have central roles in distinct stages of thymic ontogeny and be 'primed' for mutational deregulation after the acquisition of a sentinel rearrangement in specific progenitors. Consequently, this detailed portrait of the T-ALL genomic landscape offers a rational foundation for the design of genetic models of T-ALL that faithfully mirror the human disease.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
